COMPANY

Sciogen LLC

HQ: San Jose, CA source · sciogeninc.com ↗ · West Coast

Keywords: vaccine antibody influenza

Location: San Jose, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

8NIH grants

Funding and NIH signals

NIH award NIH awarded $314K (SBIR Phase I 1R43AI191860-01, new, notice Aug 21, 2026). NIH RePORTER 1R43AI191860-01 (Aug 21, 2026)
Evidence (1 event)
- Aug 21, 2026 · NIH RePORTER 1R43AI191860-01
  Organization: SCIOGEN, LLC; City/State: San Jose, CA; Project number: 1R43AI191860-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel respiratory syncytial virus therapeutics targeting G-receptor binding; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 21, 2026 Grant Government grant — SBIR: $314,363 (annual award, as published), announced Aug 21, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Mar 21, 2025 Grant Government grant — SBIR: $972,321 (annual award, as published), announced Mar 21, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Aug 21, 2026 Government grant — SBIR: $314,363 (annual award, as published), announced Aug 21, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Mar 21, 2025 Government grant — SBIR: $972,321 (annual award, as published), announced Mar 21, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 8

Annual award amounts. Total $4.6M.

Mar 21, 2024 NIH award 5R44AI149815-04 FY2024: $996,326 awarded for that fiscal year; activity R44 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Novel G protein-based RSV vaccine source ↗
Apr 25, 2023 NIH award 2R44AI149815-03 FY2023: $999,290 awarded for that fiscal year; activity R44 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Novel G protein-based RSV vaccine source ↗
Jul 12, 2021 NIH award 5R43AI149815-02 FY2021: $298,738 awarded for that fiscal year; activity R43 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Optimization of G Protein-based RSV Vaccines source ↗
Jul 27, 2020 NIH award 1R43AI149815-01A1 FY2020: $299,501 awarded for that fiscal year; activity R43 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Optimization of G Protein-based RSV Vaccines source ↗
Jul 24, 2018 NIH award 3R44AI125168-02S1 FY2018: $301,767 awarded for that fiscal year; activity R44 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Development of a novel quadrivalent seasonal influe source ↗
Jul 25, 2017 NIH award 5R44AI125168-02 FY2017: $722,269 awarded for that fiscal year; activity R44 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Development of a novel quadrivalent seasonal influenz source ↗
Jul 29, 2016 NIH award 1R44AI125168-01A1 FY2016: $737,500 awarded for that fiscal year; activity R44 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, San Jose, CA. Development of a novel quadrivalent seasonal influe source ↗
Mar 28, 2005 NIH award 1R43AI063638-01 FY2005: $256,640 awarded for that fiscal year; activity R43 (SBIR); PI LI, SHENGQIANG; recipient as written: SCIOGEN, LLC, LOS ALTOS, CA. Improved Genetically Modified H5N1 Influenza Vaccine source ↗